Targets › GPC3
19 programs from 16 companies in 21 trials: 20 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Cell surface proteoglycan. Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). (UniProt, P51654)
Open in Phaseline: the race on GPC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Newish Technology (Beijing) | NWRD06 Glypican 3 (GPC3)-targeted DNA plasmid vaccine | GPC3 | Phase 2 | Hepatocellular Carcinoma (HCC) | Dec 2028 |
| National Cancer Institute (NCI) | anti-GPC3 CAR-T cells anti-GPC3 chimeric antigen receptor (CAR) T-cell therapy | GPC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2026 |
| BeOne Medicines | BGB-B2033 Anti-glypican-3 (GPC3) antibody | GPC3 | Phase 1 | Metastatic Hepatocellular Carcinoma | Mar 2027 |
| Keymed Biosciences Co.Ltd | CM350 anti-GPC3 antibody | GPC3 | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | Codrituzumab anti-GPC3 monoclonal antibody | GPC3 | Phase 1 | Primary Extra-cranial Solid Tumor | Jun 2027 |
| AstraZeneca | AZD9793 T cell-engaging antibody targeting GPC3 on tumour cells | GPC3 | Phase 1 | Hepatocellular Carcinoma | Jun 2027 |
| Zhejiang University | CBG166 anti-GPC3 CAR-T cell therapy | GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma | Jul 2027 |
| Baylor College of Medicine | CARE T cells (15.21.GPC3-CAR T cells) Glypican-3-specific CAR T cells expressing interleukin-15 and interleukin-21 | GPC3, GPCS | Phase 1 | Liver Cancer; Hepatoblastoma; Glioblastoma Multiforme of Brain | Aug 2027 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB6426 for Injection anti-GPC3 antibody-drug conjugate | GPC3 | Phase 1 | Advanced Malignancies | Aug 2027 |
| Zymeworks BC | ZW251 anti-GPC3 antibody-drug conjugate | GPC3 | Phase 1 | Hepatocellular Carcinoma | Sep 2027 |
| Aptamer Sciences | AST-201 GPC3-targeting aptamer | GPC3 | Phase 1 | Neoplasms | Dec 2027 |
| Eastern Hepatobiliary Surgery Hospital | Super Hi-TCR-T cells Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP | PVRL4, KLRC1, TROP2, B7H3, GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Jan 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | Mesothelin/GPC3/GUCY2C-CAR-T cells CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1 | MSLN, GPC3, GUCY2C | Phase 1 | Pancreas Cancer | Mar 2029 |
| Bayer | BAY 3547926 anti-GPC3 antibody-drug conjugate with actinium-225 alpha emitter | GPC3 | Phase 1 | Hepatocellular Carcinoma | Jul 2029 |
| Second Affiliated Hospital of Guangzhou Medical University | GPC3 and/or TGFβ targeting CAR-T cells Engineered CAR-T cells targeting GPC3 and/or TGFβ with knockdown of PD1/HPK1, enhanced wit | GPC3, TGFB1 | Phase 1 | Hepatocellular Carcinoma | Aug 2029 |
| RayzeBio | RYZ801 GPC3-targeted alpha-emitting radiotherapeutic (Ac-225 conjugate) | GPC3 | Phase 1 | Hepatocellular Carcinoma (HCC) | Jun 2030 |
| Baylor College of Medicine | AGAR T cells (GPC3-CAR T cells) Glypican 3-specific chimeric antigen receptor T cells expressing interleukin-15 | GPC3 | Phase 1 | Liver Cancer | Aug 2040 |
| Baylor College of Medicine | CATCH T cells (GPC3-CAR T cells) IL-15 armored glypican 3-specific chimeric antigen receptor T cells | GPC3 | Phase 1 | Liver Cell Carcinoma | Dec 2040 |
| SOTIO Biotech | BOXR1030 anti-GPC3 CAR-T cell therapy | GPC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2042 |
Hepatocellular Carcinoma (6) Hepatocellular Carcinoma (HCC) (2) Liver Cancer (2) Advanced Solid Tumor (1) Neoplasms (1) Advanced Hepatocellular Carcinoma (1) Advanced Malignancies (1) Liver Cell Carcinoma (1) Hepatoblastoma (1) Glioblastoma Multiforme of Brain (1) Primary Extra-cranial Solid Tumor (1) Advanced Hepatocellular Carcinoma (HCC) (1)
other (8), small molecule (6), protein or peptide (2), mixed (2), antibody (1)
Baylor College of Medicine (3) Second Affiliated Hospital of Guangzhou Medical University (2) AstraZeneca (1) Keymed Biosciences Co.Ltd (1) Newish Technology (Beijing) (1) Aptamer Sciences (1) National Cancer Institute (NCI) (1) Zhejiang University (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Zymeworks BC (1) RayzeBio (1) SOTIO Biotech (1) Bayer (1) Memorial Sloan Kettering Cancer Center (1) Eastern Hepatobiliary Surgery Hospital (1) BeOne Medicines (1)
TGFB1 (1) GPCS (1) PVRL4 (1) KLRC1 (1) TROP2 (1) B7H3 (1) MSLN (1) GUCY2C (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.